DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Positive impactIPO

Molbio Diagnostics IPO Day 1: Check subscription status, price band, lot size and key dates

Dailyhunt 1 hr ago·10 Aug 2026, 6:16 am

Molbio Diagnostics has kicked off its initial public offering (IPO) on Day 1, inviting retail investors to participate. The company is offering shares in the price band of ₹[Price Band] to ₹[Price Band], with a lot size of [Lot Size] shares. This subscription window will remain open until [Closing Date], allowing investors to bid for their desired quantity before the issue closes.

For investors, Molbio's IPO represents an opportunity to gain exposure to the diagnostics sector, which has seen growing demand. The company's financial performance and the overall market sentiment will be key factors to consider before applying. Investors should review the company's risk factors and valuation metrics carefully.

Going forward, the focus will be on the subscription numbers over the next few days. The IPO is expected to list on [Listing Exchange] on [Listing Date]. Keep an eye on the grey market premium (GMP) and the final allotment status to gauge the market's reception.

Excerpt from Dailyhunt

T he initial public offering of point-of-care diagnostics company Molbio Diagnostics Ltd opened for subscription on Monday, August 12. The issue will end on August 12. The price band has been fixed at ₹768 to ₹807 per share. The ₹939.70 crore initial share sale is a mix of fresh issuance of shares totalling ₹200 crore…

Read the original at Dailyhunt

Affected stocks

Bullish1 stock

128

Molbio Diagnostics

1286089 Bullish

—

Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.

Key takeaways

Concerns Molbio Diagnostics (1286089).
Category: IPO.
AI reads the tone as positive (potentially bullish) for the stock.
Assessed as a significant, market-relevant update.

Why it matters

A meaningful update for Molbio Diagnostics worth tracking. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.

Summary & analysis by DocStoX. Full story at Dailyhunt.